Karuna Therapeutics, Inc. - Common Stock (NQ:KRTX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Karuna Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Travelzoo, Semler Scientific, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday ↗

March 22, 2023

U.S. stocks traded mostly higher, with the Dow Jones gaining around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Karuna Therapeutics Announces Pricing of Public Offering of Common Stock

March 21, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 21, 2023

Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share.

Via Benzinga

Analyst Expectations for Karuna Therapeutics's Future ↗

March 21, 2023

Via Benzinga

Karuna Therapeutics Announces Proposed Public Offering of Common Stock

March 20, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

ENPH Stock Price Prediction: Can Enphase Energy Really Hit $225? ↗

March 20, 2023

Enphase Energy (ENPH) stock is continuing to rise higher on Monday after an upgrade on Friday gave the company's shares a boost.

Via InvestorPlace

UBS Stock Price Prediction: Why This Analyst Says UBS Is a ‘Buy’ ↗

March 20, 2023

UBS (UBS) stock is a hot topic among traders on Monday with one analyst offering a new rating for the financial company's shares.

Via InvestorPlace

Karuna Therapeutics Says It One Step Closer To Potential Treatment Option After Encouraging Schizophrenia Data ↗

March 20, 2023

Via Benzinga

Why Is Karuna Therapeutics (KRTX) Stock Moving Today? ↗

March 20, 2023

Karuna Therapeutics (KRTX) stock is on the move Monday after releasing positive results from a Phase 3 clinical trial for KarXT.

Via InvestorPlace

Karuna Surges To Three-Month High On Another Win In Schizophrenia ↗

March 20, 2023

The company is soon planning to ask for FDA approval of KarXT.

Via Investor's Business Daily

The Latest Analyst Ratings for Karuna Therapeutics ↗

March 02, 2023

Via Benzinga

Looking Into Karuna Therapeutics's Return On Capital Employed ↗

February 28, 2023

Via Benzinga

Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

March 20, 2023

From Zai Lab Limited

Via GlobeNewswire

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

March 20, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023 ↗

March 08, 2023

Via Benzinga

Analyst Expectations for Karuna Therapeutics's Future ↗

January 27, 2023

Via Benzinga

5 Analysts Have This to Say About Karuna Therapeutics ↗

December 09, 2022

Via Benzinga

What 5 Analyst Ratings Have To Say About Karuna Therapeutics ↗

December 09, 2022

Via Benzinga

Ciena, Apple And 3 Stocks To Watch Heading Into Monday ↗

March 06, 2023

With US futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Target To Rally 20%? Here Are 10 Other Analyst Forecasts For Thursday ↗

March 02, 2023

Bernstein raised the price target for Okta, Inc. (NASDAQ: OKTA) from $80 to $92. Bernstein analyst Peter Weed maintained a Market Perform rating. Okta shares jumped 16.2% to $83.00 in pre-market...

Via Benzinga

Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates

February 23, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Karuna Therapeutics to Present at the SVB Securities Global Biopharma Conference

February 09, 2023

From Karuna

Via Business Wire

Where Karuna Therapeutics Stands With Analysts ↗

December 09, 2022

Via Benzinga

Expert Ratings for Karuna Therapeutics ↗

December 09, 2022

Via Benzinga

Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing' ↗

February 03, 2023

Via Benzinga

Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates

February 02, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer

January 31, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023 ↗

January 27, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.